Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Overview
Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Companies Involved in Therapeutics Development
Jyant Technologies Inc
Neurotez Inc
Regeneron Pharmaceuticals Inc
XL-protein GmbH
Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Drug Profiles
Allo-Aca - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CV-08 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
memtin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
metreleptin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peptide to Antagonize Leptin Receptor II for Triple Negative Breast Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombint Protein to Agonize Leptin Receptor for Obesity - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
REGN-4461 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
XL-100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Dormant Products
Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Discontinued Products
Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Product Development Milestones
Featured News & Press Releases
Aug 23, 2018: Novelion Therapeutics announces next phase of operatiol improvements
Jul 31, 2018: Novelion Therapeutics Announces Marketing Authorization for MYALEPTA (metreleptin) in the European Union to Treat Generalized and Partial Lipodystrophy
Jun 25, 2018: Novelion Therapeutics Announces Presentation of Positive Metreleptin Data at American Diabetes Association Scientific Sessions
Jun 01, 2018: MYALEPTA (metreleptin) Receives Positive CHMP Opinion in Patients with Generalized and Partial Lipodystrophy
Sep 15, 2017: Metreleptin and Lipodystrophy Data Presented at the Intertiol Meeting of Pediatric Endocrinology
Jun 12, 2017: Novelion Therapeutics Announces Presentation of Metreleptin Data at American Diabetes Association
May 05, 2017: Novelion Therapeutics Announces Presentation of Metreleptin Data at American Association of Clinical Endocrinology
Apr 04, 2017: Metreleptin and Lipodystrophy Data Presented at the Annual Meeting of the Endocrine Society
Mar 30, 2017: Novelion Therapeutics Subsidiary Announces New Data to be Presented at the Annual Meeting of the Endocrine Society
Jan 23, 2017: Novelion Therapeutics Announces Acceptance of Marketing Authorization Application for Metreleptin by European Medicines Agency
Dec 22, 2016: Novelion Therapeutics Subsidiary Files for European Approval for Metreleptin as a treatment for Generalized Lipodystrophy and a Subset of Patients with Partial Lipodystrophy
Nov 03, 2016: Aegerion Pharmaceuticals appoints John Orloff as Executive Vice President Head of R&D
Nov 03, 2016: Aegerion Pharmaceuticals appoints John Orloff as Executive Vice President, Head of R&D
Nov 03, 2016: Aegerion Pharmaceuticals appoints John Orloff, M.D., as Executive Vice President, Head of R&D
Feb 25, 2014: FDA approves Myalept to treat rare metabolic disease
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development by Stage of Development, H1 2019
Number of Products under Development by Therapy Areas, H1 2019
Number of Products under Development by Top 10 Indications, H1 2019
Number of Products by Mechanism of Actions, H1 2019
Number of Products by Stage and Mechanism of Actions, H1 2019
Number of Products by Routes of Administration, H1 2019
Number of Products by Stage and Routes of Administration, H1 2019
Number of Products by Molecule Types, H1 2019
Number of Products by Stage and Molecule Types, H1 2019


List of Tables


Number of Products under Development by Stage of Development, H1 2019
Number of Products under Development by Therapy Areas, H1 2019
Number of Products under Development by Indication, H1 2019
Number of Products under Development by Companies, H1 2019
Products under Development by Companies, H1 2019
Number of Products by Stage and Mechanism of Actions, H1 2019
Number of Products by Stage and Route of Administration, H1 2019
Number of Products by Stage and Molecule Type, H1 2019
Pipeline by Jyant Technologies Inc, H1 2019
Pipeline by Neurotez Inc, H1 2019
Pipeline by Regeneron Pharmaceuticals Inc, H1 2019
Pipeline by XL-protein GmbH, H1 2019
Dormant Projects, H1 2019
Discontinued Products, H1 2019